Compare HPP & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPP | MASS |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | 607 | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.5M | 265.5M |
| IPO Year | N/A | 2020 |
| Metric | HPP | MASS |
|---|---|---|
| Price | $11.29 | $8.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $12.63 | $12.00 |
| AVG Volume (30 Days) | ★ 1.3M | 260.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | N/A | $19.44 |
| Revenue Next Year | $6.81 | $18.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $4.20 |
| 52 Week High | $14.95 | $9.34 |
| Indicator | HPP | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 70.73 | 67.20 |
| Support Level | $9.96 | $7.56 |
| Resistance Level | $11.26 | $9.25 |
| Average True Range (ATR) | 0.78 | 0.47 |
| MACD | 0.23 | 0.13 |
| Stochastic Oscillator | 75.69 | 83.77 |
Hudson Pacific Properties Inc is a vertically integrated real estate investment trust offering end-to-end real estate solutions for dynamic tenants in the synergistic, converging and secular growth industries of tech and media. It acquires, repositions, develops and operates sustainable high-quality office studio properties in high-barrier-to-entry tech and media epicenters. Its primary investment markets include Los Angeles, the San Francisco Bay Area, Seattle, New York and Vancouver, British Columbia. Its segments include Office properties and related operations and Studio properties and related operations. The majority of the revenue is derived from Office properties and related operations segment.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.